Search - tctmd.com

Displaying 1 - 20 of 83

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Michael O'Riordan

December 13, 2017

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Daily News

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Michael O'Riordan

December 07, 2017

News Daily News

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

Caitlin E. Cox

December 05, 2017

News Daily News

Diabetes Remission Possible With Significant Weight Loss: DiRECT

Michael O'Riordan

December 05, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Conference News AHA 2017

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

Michael O'Riordan

November 16, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Yael L. Maxwell

October 30, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Proximity to Physical Activity Facilities May Play Role in Body Fat Levels

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Surviving CVD: Obesity Offers No Protection for Those With New Onset Cardiac Events

Myocardial Injury After Noncardiac Surgery Linked With Higher 1-Year Mortality

Diabetes Remission Possible With Significant Weight Loss: DiRECT

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Sustained Blood Pressure Reductions With Gastric Bypass Surgery: GATEWAY

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

PCSK9 Inhibitors: More Data Show Disappointing Approval Rates of Prescriptions by Payers

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Statins and Diabetes: Causal Link Reinforced in New Analysis

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content